


WEDNESDAY
PROGRAMME
3 MAY 2023



09:00 – 09:15

Welcome & Opening Address

Michael Ison
DMID/NIAID/NIH, Rockville, MD, USA

09:15 – 10:00

Opening Keynote

Chair: Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA

The Development of Small Molecules for the Treatment of Respiratory Viral Illnesses: Important Lessons From A Burgeoning New Era

Richard Whitley
University of Alabama, Birmingham, AL, USA

SESSION

1

10:00 – 11:30

PRECLINICAL – VIRAL TARGETS

Co-Chairs: Lieve Naesens, Rega Institute, Leuven, Belgium and Hui-Ling Yen, University of Hong Kong, Hong Kong SAR, China

10:05 – 10:30

Insights from Coronavirus Replication in Developing Antivirals

Mark Denison
Vanderbilt University Medical Center, Nashville, Tennessee, USA

10:30 – 10:55

A Molecularly Engineered Lectin for the Prevention and Treatment of Influenza and Coronaviruses

David Markovitz
University of Michigan, Ann Arbor, MI, USA

10:55 – 11:20

Non-nucleoside RSV Polymerase Inhibitor

Richard Plemper
Georgia State University, Atlanta, GA, USA

11:20 – 11:30

Panel Discussion

11:30 – 11:45 Coffee Break

SESSION

2

11:45 – 13:15

PRECLINICAL – HOST-DIRECTED ANTIVIRAL THERAPEUTICS

Co-Chairs: Bin Cao, Capital Medical University, Beijing, China and Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France

11:50 – 12:15

Harnessing Interferon Responses as Potential Broad Spectrum Respiratory Antiviral Treatments

Evangelos Andreakos
Biomedical Research Foundation, Academy of Athens, Greece

12:15 – 12:40

Towards a Novel Host-targeted Anti-infective Strategy for COVID-19 and Other Acute Respiratory Viral Diseases

Stephan Ludwig
Westfaelische-Wilhelms-University, Münster, Germany

12:40 – 13:05

Combined Inhibition of Viral and Host Factors to Maximize Antiviral Activity

Sara Cherry

University of Pennsylvania, Philadelphia PA, USA

13:05 – 13:15

Panel Discussion

13:15 – 14:15 Lunch and Poster Viewing

SESSION

3

ORAL ABSTRACT SESSION 1 – PRECLINICAL DEVELOPMENT

Co-Chairs: Mark Denison, Vanderbilt University Medical Center, Nashville, Tennessee, USA and Rich Whitley, University of Alabama, Birmingham, AL, USA

14:15 – 15:45

14:15 – 14:30

Preclinical Antiviral Profile of ALG-097558, a Novel Pan-Coronavirus 3CL Protease Inhibitor (AASU0006)

Andreas Jekle

Aligos Therapeutics, South San Francisco, CA, USA

14:30 – 14:45

CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates Potent, Universal Activity Against Influenza A and B (AASU0009)

James Levin

Cidara Therapeutics, San Diego, CA, USA

14:45 – 15:00

A Pseudovirus-based System for Mapping the Antigenic Effects of Thousands of Mutations in SARS-CoV-2 Spike (AASU0045)

Bernadeta Dadonaite

Fred Hutchinson Cancer Center, Seattle, WA, USA

15:00 – 15:15

Preclinical Development of Optimized DHODH Inhibitors as Broad-Spectrum Antivirals for the Treatment of Respiratory Virus Infections (AASU0039)

Hella Kohlhof

Immunic AG, Gräfelfing, Germany

15:15 – 15:30

Inhaled Muco-trapping Monoclonal Antibody for Effective Therapy Against Respiratory Syncytial Virus Infections in Lambs (AASU0047)

Sam Lai

University of North Carolina, Chapel Hill, NC, USA

15:30 – 15:45

Live Imaging of Airway Epithelium Reveals Mucociliary Clearance Modulates Spread of SARS-CoV-2 (AASU0034)

Mark Becker

Northwestern University, Chicago, IL, USA

15:45 – 16:05 Coffee Break

SESSION**4****16:05 – 17:45****CLINICAL TRIAL DESIGN ISSUES/
HUMAN CHALLENGE/OMICS**

Co-Chairs: Nelson Lee, University of Toronto, Toronto, Canada and
Cameron Wolfe, Duke University Medical Center, NC, USA

16:10 – 16:25**Randomized, Placebo Control Trials including of
EUA Drugs**

John Beigel
NIAID/NIH, Rockville, MD, USA

16:25 – 16:40**The RECOVERY Trial: Lessons and Legacy**

Peter Horby
University of Oxford, Oxford, UK

16:40 – 16:55**The SARS-CoV-2 Human Challenge Model**


Chris Chiu
Imperial College, London, UK

16:55 – 17:10**Use of Omics Approaches in the Context of Clinical Trials:
Development of Improved Influenza Interventions**

Teresa Aydillo
Icahn School of Medicine at Mount Sinai, New York, NY, USA

17:10 – 17:25**Fully Remote Trials**

Caleb Skipper
University of Minnesota, Minneapolis, MN, USA

17:25 – 17:45**Panel Discussion**

THURSDAY

PROGRAMME

4 MAY 2023

SESSION**5****8:30 – 10:45****UPDATES ON CLINICAL TRIALS**

Co-Chairs: David Hui, The Chinese University of Hong Kong, Hong Kong
SAR, China and Helen Chu, University of Washington, Seattle, WA, USA

08:35 – 09:05**Keynote Talk****REMAP-CAP: Preparing for the Pandemic and Translating
the Network into Seasonal Threats**

Srinivas Murthy
BC Children's Hospital, Vancouver, Canada

09:05 – 09:25**Clinical Trials of Severe Viral Pneumonia**

Bin Cao
China-Japan Friendship Hospital, Beijing, China

09:25 – 09:45

Monoclonal Antibodies – Current State of the Art and Future Directions

James Crowe

Vanderbilt University Medical Center, Nashville, Tennessee, USA

09:45 – 10:05

Antiviral Respiratory Viral Therapies for Children

Janet Englund

Seattle Children's Hospital, Seattle, WA, USA

10:05 – 10:25

Small Molecules and Antibodies for RSV

Angela Branche

University of Rochester Medical Center, Rochester, NY, USA

10:25 – 10:45

Panel Discussion

10:45 – 11:05 Coffee Break

SESSION

6

11:05 – 12:35

ORAL ABSTRACT SESSION 2 – ANTIVIRALS, MONOCLONAL ANTIBODIES AND COMBINATIONS

Co-Chairs: Emi Takashita, National Institute of Infectious Diseases, Tokyo, Japan and Tim Uyeki, CDC, Atlanta, GA, USA

11:05 – 11:20

First-in-Human Study of CC-42344, a Novel Broad-Spectrum Influenza A Polymerase PB2 Inhibitor (AASU0024)

Sam Lee

Cocrystal Pharma Inc., Bothell, WA, USA

11:20 – 11:35

Safety and Efficacy Results from Phase 1 and 2a H1N1 Challenge Trials Using an Anti-Type A and B Influenza Immunotherapeutic that is also Synergistic with Oseltamivir in Mice (AASU0041)

Thomas Luke

SAB Biotherapeutics, Sioux Falls, SD, USA

11:35 – 11:50

CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates a High Barrier to Resistance and Retains Potent Activity Against Neuraminidase Inhibitor-Resistant Influenza A and B (AASU0008)

Simon Döhrmann

Cidara Therapeutics, San Diego, CA, USA

11:50 – 12:05

Exploratory Evaluation on the Effect of Ensitrelvir for Long COVID: a Post-Hoc Analysis of Phase 3 Part of Phase 2/3 in Patients with Mild-to-Moderate COVID-19 (AASU0012)

Akimasa Fukushi


Shionogi & Co., Ltd, Osaka, Japan

12:05 – 12:20

Clinical Trials of Inhaled Interferon Beta-1a (SNG001) in COVID-19 Patients in the Home and Hospital Settings (AASU0014)

Phillip Monk

Synairgen Research Ltd, Southampton, Hants, UK



THURSDAY
PROGRAMME
4 MAY 2023

12:20 – 12:35

**Ensitrelvir for Symptomatic and Mild Symptoms Only:
COVID-19 Patients in Phase 2b/3 Part (AASU0010)**

Genki Ichihashi
Shionogi & Co., Ltd, Osaka, Japan

12:35 – 14:15

SPONSORED LUNCH SEMINAR

**Combination Therapy to Treat Respiratory Infections:
Ready for Primetime?**

12:55 – 13:00

Introduction

Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA, and
TBC Bill & Melinda Gates Foundation, Seattle, Washington, USA

13:00 – 13:20

**The Challenges of Monotherapy – a View from the
Immunocompromised Host –**

Michael Boeckh
Fred Hutchinson Cancer Center, Seattle, WA, USA

13:20 – 13:40

**Combination Antiviral Therapy for RVIs: Update on
Clinical Progress**

Frederick Hayden
University of Virginia School of Medicine, Charlottesville, VA, USA

13:40 – 14:00

Antivirals plus Immune Modulators

John Beigel
NIAID/NIH, Rockville, MD, USA

14:00 – 14:15

Panel Discussion

SESSION

7

CLINICAL TRIAL AND REGULATORY ISSUES

Co-Chairs: Frederick Hayden, University of Virginia School of Medicine,
Charlottesville, VA, USA and Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA

14:15 – 16:15

14:20 – 14:40

**Regulatory Framework for Moving from EUA to FDA
Approval for Antiviral Products**

Stephanie Troy
US FDA, Silver Spring, MD, USA

14:40 – 15:00

**Clinical Trial Endpoints for Approval of Antiviral
Therapeutics**

Marco Cavaleri
EMA, Amsterdam, The Netherlands

15:00 – 15:20

Combination Therapy

Mariana Baz
CHU de Québec-Université Laval, Québec, Canada

SESSION**8****16:10 – 18:10****15:20 – 15:40****The Path Forward for the Treatment of Hospitalized Influenza Patients: Host-Targeted Therapeutics**

Kimberley Armstrong
BARDA, Washington DC, USA

15:40 – 15:50**Panel Discussion****15:50 – 16:10 Coffee Break & Poster viewing****TREATMENT UPDATES & ORAL ABSTRACT SESSION 3**

Co-Chairs: Kimberley Armstrong, Biomedical Advanced Research and Development Authority (BARDA), Washington DC, USA and Shikha Garg, CDC, Atlanta, GA, USA

16:10 – 16:55**State of the Art of COVID-19 Therapy**

Cameron Wolfe
Duke University Medical Center, Durham, NC, USA

16:55 – 17:10**Comparison of the Effectiveness of Baloxavir Marboxil and Oseltamivir in Reducing Household Transmission of Influenza**

(AASU0004)

Takamichi Baba
Shionogi & Co., Ltd, Osaka, Japan

17:10 – 17:25**Heterogeneity of Influenza Infection Severity at Hospital Admission Significantly Confounds Analysis of Antiviral Effectiveness on Reducing Hospital Length of Stay (AASU0038)**

Aleda Leis
University of Michigan, Ann Arbor, MI, USA

17:25 – 17:40**Pharmacokinetics of an Extended Half-Life Monoclonal Antibody Against COVID-19 in Hematopoietic Stem Cell Transplant Recipients**

(AASU0007)

Jim Boonyaratanakornkit
Fred Hutchinson Cancer Center, Seattle, WA, USA

17:40 – 17:55**Trial in Progress: a Phase I/III, Randomised Controlled Pre-exposure Prophylaxis Study of the Anti-SARS-CoV-2 Antibody AZD3152 (SUPERNOVA) (AASU0016)**

Taylor Cohen
AstraZeneca, Gaithersburg, MD, USA

17:55 – 18:10**Meta-Analysis and Validation of OMICs Data from COVID-19 Patient Samples Reveal Auranofin as a Promising Therapeutic Agent (AASU0046)**

Shashank Tripathi
Indian Institute of Science, Bengaluru, Karnataka, India

18:10 – 19:10**Poster Reception and Poster viewing**

FRIDAY
PROGRAMME
5 MAY 2023



08:30 – 08:40

Introduction to Roberts/Tisdale Lectureship

Maria Zambon

UK Health Security Agency (UKHSA), London, UK / Chair of ISIRV

08:40 – 09:25

Keynote Talk – Roberts/Tisdale Lectureship

Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Maria Zambon, UK Health Security Agency (UKHSA), London, UK

Resistance to Antivirals Targeting Respiratory Viruses: When Does it Matter?

Wendy Barclay

Imperial College, London, UK

SESSION

9

09:25 – 10:55

THE RIGHT DRUG FOR THE RIGHT PATIENT: OPTIMIZING ANTIVIRAL TREATMENT

Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Maria Zambon, UK Health Security Agency (UKHSA), London, UK

09:30 – 09:55

Role of Genomic Surveillance in Tracking Emergence of Resistance Over Time

Adam Lauring

University of Michigan, Ann Arbor, MI, USA

09:55 – 10:20

Developing Diagnostics to Optimize Antiviral Use

Lisa Ng

A* STAR Infectious Diseases Labs, Singapore

10:20 – 10:45

Role of Misinformation and Erosion of Social Trust in Response to Pandemics

Rachel Moran

University of Washington, Seattle, WA, USA

10:45 – 10:55

Panel Discussion

10:55 – 11:15 Coffee Break

SESSION

10

11:15 – 12:45

ORAL ABSTRACT SESSION 4 – SURVEILLANCE & ANTIVIRAL RESISTANCE


Co-Chairs: Nelson Lee, University of Toronto, Toronto, Canada and Arnold Monto, University of Michigan, Ann Arbor, MI, USA

11:15 – 11:30

Implementation of Cell Culture-Based Assay IRINA for Baloxavir Susceptibility Monitoring, 2022-23 Influenza Season (AASU0018)

Mira Patel

CDC, Atlanta, GA, USA



11:30 – 11:45

ViralVar: A Web Tool for Multilevel Visualization of SARS-CoV-2 Genomes (AASU0020)

Arghavan Alisoltani
Northwestern University, Chicago, IL, USA

11:45 – 12:00

Utilization of Whole Genome Sequencing to Augment Traditional Contact Tracing for a University SARS-CoV-2 Outbreak (AASU0044)

Cameron Wolfe
Duke University Medical Center, Durham, NC, USA

12:00 – 12:15

Whole Genome Sequencing Exploring Evolution Associated with the Combined Effect of Oseltamivir and Favipiravir on Influenza Virus

(AASU0011)
Shengrui Mu
China-Japan Friendship Hospital, Beijing, China

12:15 – 12:30

Intra-host Population Dynamics of a SARS-CoV-2 Delta-Omicron Superinfection in an Immunocompromised Pediatric Patient

(AASU0021)
Lacy Simons
Northwestern University, Chicago, IL, USA

12:30 – 12:45

Altered RSV Population Structures in Adult Populations Following COVID-19 Mitigation Strategies (AASU0036)

Estefany Rios Guzman
Northwestern University, Chicago, IL, USA

12:45 – 13:45 Lunch

SESSION

11

ACCESS TO CARE/GLOBAL ROLLOUT

Co-Chairs: Helen Chu, University of Washington, Seattle, WA
USA and TBC

13:45 – 14:50

13:50 – 14:15

Global Public Health Security and Justice for Vaccines and Therapeutics in the COVID-19 Pandemic

Sylvie Briand
WHO, Geneva, Switzerland

14:15 – 14:40

Enabling Access to Medical Countermeasures by Underserved Populations

Meghan Pennini
HHS, Washington, DC, USA

14:40 – 14:50

Panel Discussion

14:50 – 15:00

Summary & Close